Zymeworks (Nasdaq: ZYME), a clinical-stage biotech developing antibody-based therapies for cancer and immune diseases, has ...

Physician attitudes toward patient choice between the use of biologics and biosimilars vary widely across global markets, ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

Russian public procurements of drugs based on the active ingredient semaglutide, which is an original drug from Denmark’s ...

South Korea-based biotech firms 1ST Biotherapeutics and LigaChem Biosciences (Kosdaq: 141080) have entered a strategic partnership to co-develop next-generation antibody-drug conjugates and small ...

London, UK-based Alis Biosciences, an investment fund focused on returning capital to investors that is currently trapped in ...

The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a ...

On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in ...

The National Board of Health and Welfare will pay 80 million kronor ($8.3 million) to the national initiative Genomic ...

The DESTINY-Breast09 Phase III trial of AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab ...

The US Food and Drug Administration (FDA) has granted another approval for Dupixent (dupilumab), for the treatment of adults ...

In keeping with US Department of Health and Human Services Secretary Robert F Kennedy Jr’s promise to carry out the ...